Description:
CALGB 90802 Registration Worksheet Form Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=879626AD-DB8C-4AF2-E040-BB89AD4364E1
Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=879626AD-DB8C-4AF2-E040-BB89AD4364E1Keywords:
Versions (4)
- 12/18/14 12/18/14 - Martin Dugas
- 1/9/15 1/9/15 - Martin Dugas
- 1/9/15 1/9/15 - Martin Dugas
- 9/20/21 9/20/21 -
Uploaded on:
September 20, 2021
DOI:
To request one please log in.License :
Creative Commons BY-NC 3.0 LegacyModel comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Kidney Cancer NCT01198158 Registration - CALGB 90802 Registration Worksheet Form - 3103555v1.0
Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors
- StudyEvent: CALGB 90802 Registration Worksheet Form